Vilon

Vilon is a synthetic dipeptide (Lys-Glu, lysine-glutamic acid) and one of the first peptide bioregulators developed in the Khavinson research programme at the St. Petersburg Institute of Biogerontology. As a dipeptide, it is structurally among the simplest members of the bioregulator family - yet it has accumulated one of the most substantial research records of any compound in this series.

The simplicity of Vilon is both a scientific curiosity and a practical advantage. That a two-amino-acid dipeptide could produce measurable effects on immune function and longevity challenged assumptions about the minimum complexity required for biologically meaningful peptide signalling. The dipeptide's development emerged from studies isolating active peptides from thymic extract and immune tissue - with Khavinson's group demonstrating that small dipeptides and tripeptides could concentrate within cell nuclei and interact with gene regulatory regions.

Vilon's primary research focus has been immune function, particularly T-cell regulation and NK (natural killer) cell activity. Immunosenescence - the age-related decline of immune competence - is driven partly by thymic involution (loss of T-cell generation capacity) and partly by functional exhaustion of existing immune cells. Vilon has been studied for its ability to restore immunological parameters in aged experimental animals and elderly human subjects, including T-lymphocyte counts, IL-2 production, and NK cell cytotoxicity.

The longevity data for Vilon is perhaps the most compelling aspect of its research profile. Long-running Russian cohort studies of elderly subjects treated with bioregulator combinations (including Vilon and Epitalon) showed significant reductions in all-cause mortality over 8-15 year follow-up periods. These findings, while requiring replication in controlled Western-style clinical trials, have sustained substantial research interest in Vilon as a longevity peptide.

Vilon is frequently combined with Epitalon in longevity-focused research protocols. While Epitalon targets the neuroendocrine system (pineal gland, telomere maintenance), Vilon targets the immune system - together addressing two major systems associated with healthy ageing.